Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Identity Ambiguity: The Core Finding

"Ping Yi" is not a single traceable scientist in the supplied evidence. The OpenAlex disambiguation returns several distinct high-output researchers (e.g., Yi-Ping Joseph Woo, h-index 78; Yuanping Yi, h-index 90; Yi-Ping Cui, h-index 62), none matching a unified "Ping Yi." Worse, the OpenAlex "top_author" record is internally inconsistent: its top works are ACC/AHA cardiology guidelines authored by O'Gara, Kushner, and others — with "Yi-Ping Joseph Woo" nowhere on those author lists — indicating entity-resolution failure, likely citation-stacking from guideline mega-papers Cardiology forecasting paper (attribution mismatch).

The paper corpus itself spans demonstrably different people: the CTTNBP2 study is funded to Yi-Ping Hsueh at Academia Sinica CTTNBP2 microtubule study (Hsueh); the SIRT2/G6PD leukemia study credits Yi-Ping Wang (NSFC 81502379) SIRT2-G6PD AML study (Yi-Ping Wang); the bone-signaling review credits Yi-Ping Li at UAB TGF-β/BMP bone review (Yi-Ping Li); and the granite paper uses "Ping Yi" strictly as a Shandong location Granite thermal-shock study (location). Other records (Taiwan TCM use, TLCA consensus, RbohF rice, integrin/cell-biology papers) originate from unrelated Chinese/Taiwanese groups Pediatric TCM allergic rhinitis study Rice RbohF ROS pollen study.

Figure: The rated quality is uniformly high (mean ≈ 8.0/10) but these scores reflect extraction-level assessments of papers, not a single author's attributable output.

Scientific Strength of the Attributable Cluster (Caveated)

If we judge the papers plausibly tied to Yi-Ping-named researchers, the signatures are strong: mechanistic cell-biology rigor with explicit sample sizes (e.g., n=123 BP2-transfected cells vs n=120 GFP controls; rescue experiments) CTTNBP2 mechanistic rigor; metabolism work connecting enzymology to TCGA survival associations (G6PD-high p=0.0069; SIRT2-high p=0.0152, n=173) SIRT2-G6PD survival data; and large-scale trial leadership in pediatric ALL (2,231 enrolled; 5-yr EFS 79.9% ± 0.9) with an MRD-guided pilot showing lower relapse (CIR 10.7% vs 18.0%, P<0.001) CCLG-ALL 2008 outcomes.

Blind Spots and What Would Change This Review

The honest conclusion is epistemic humility: without verified ORCID linkage, per-paper author-position data, or self-citation networks, I cannot defensibly assign these works to one individual. What would resolve it: ORCID-crossed author lists for each DOI, affiliation timelines, and first/senior-authorship distribution. Recurrent weaknesses across the corpus that would also temper any author score: reliance on cell-line/overexpression systems, small in-vivo groups (n=5 xenografts EphA2 NPC study limitations), absence of blinding in some virotherapy experiments Oncolytic HSV glioblastoma study, and non-randomized comparisons (MRD pilot) MRD non-randomized limitation.

 BGPT Author Review

Scientific Quality

No single "Ping Yi" can be verified; the corpus fragments across at least four distinct Yi-Ping researchers plus one location name. Papers plausibly attributable (Hsueh, Wang, Li) show strong mechanistic design, rescue experiments, and independent cohort validation, but attribution itself is the dominant red flag — scoring any individual from this pool would be confabulation. The OpenAlex top match is also internally inconsistent (cardiology guidelines with no Yi-Ping on author lists), suggesting inflated, entity-resolution-error citation metrics (41k citations, h-index 78) that should not be trusted as evidence of personal scientific quality.

Communication Quality

Papers in the cluster use clear figures, explicit n-values, and declared limitations, typical of competent mid-to-senior cell-biology and clinical-trial communication. Some records (granite, resilience engineering) are field-jargon-dense and belong to entirely different authors/disciplines, so communication quality is judged only on the plausibly attributable subset and remains an estimate under attribution uncertainty.

Author Novelty

Several works are genuinely novel for their time: cytoplasmic-tail swaps defining integrin inside-out signaling (1994-1995), MRD-guided risk stratification piloted nationally in China (2018), and engineered OV-CDH1 oncolytic virus (2018). However, the spread across unrelated disciplines again indicates multiple authors, so novelty cannot be coherently credited to one person.

Scientific Rigor

Within the attributable papers, rigor is solid: controls, rescue experiments, independent validation cohorts, and stated limitations. Deductions for non-randomized MRD deployment, n=5 xenograft groups, absent blinding in some in vivo work, and reliance on overexpression systems — all explicitly acknowledged but still constraining causal inference.